SHR-1905
Phase 3Small molecule
Guangdong Hengrui Pharmaceutical Co., LtdSHR-1905 is one of 38 small molecule programs targeting Chronic Rhinosinusitis With Nasal Polyps. It is currently in Phase 3.
2
Indications
7
Total Trials
4
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
175 competitors in Asthma
#DrugCompanyPhaseTrials
1SHR-1905
Guangdong Hengrui Pharmaceutical Co., LtdPhase 3
Celexa
AbbViePreclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
DUPIXENT
RegeneronPreclinical
Paracetamol
GSKPreclinical
Blood Withdrawn
Emergent BioSolutionsPreclinical
Aclidinium Bromide
AstraZenecaPreclinical
Blood Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Lexapro
SShirley Ryan AbilityLab
Preclinical
Biological Drug
UUniversitaire Ziekenhuizen KU Leuven
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Asthma3 trials
Chronic Rhinosinusitis With Nasal Polyps2 trials
Atopic Dermatitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHR-1905. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details